The FDA has granted 510(k) clearance to Asthmapolis’s asthma sensor system and mobile app. The sensor attaches to the top of an MDI canister, records data from an accelerometer and GPS receiver, and transmits the data wirelessly to a patient’s smart phone. The device uses GPS data to record where and when the inhalers are used, providing information to public health organizations to track the incidence of inhaler use in specific locations.
Asthmapolis Chief Regulatory Officer Inger Couture said, “We are thrilled to have achieved this important milestone to support our mission of providing tools to help patients and their healthcare providers better understand and control their asthma symptoms. Despite all we know about asthma and how to treat it, the majority of patients still do not have the disease under control, and traditional approaches to self-management have been time-consuming and complicated. The Asthmapolis technology makes it much easier to track symptoms and use of metered dose inhalers, allowing patients, their families and their doctors to gain a valuable new perspective on the disease.”
Read the Asthmapolis press release.
